These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 15292289)

  • 1. Steroid profiling by tandem mass spectrometry improves the positive predictive value of newborn screening for congenital adrenal hyperplasia.
    Minutti CZ; Lacey JM; Magera MJ; Hahn SH; McCann M; Schulze A; Cheillan D; Dorche C; Chace DH; Lymp JF; Zimmerman D; Rinaldo P; Matern D
    J Clin Endocrinol Metab; 2004 Aug; 89(8):3687-93. PubMed ID: 15292289
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Steroid profiling for congenital adrenal hyperplasia by tandem mass spectrometry as a second-tier test reduces follow-up burdens in a tertiary care hospital: a retrospective and prospective evaluation.
    Seo JY; Park HD; Kim JW; Oh HJ; Yang JS; Chang YS; Park WS; Lee SY
    J Perinat Med; 2014 Jan; 42(1):121-7. PubMed ID: 23989111
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Newborn screening for congenital adrenal hyperplasia: additional steroid profile using liquid chromatography-tandem mass spectrometry.
    Janzen N; Peter M; Sander S; Steuerwald U; Terhardt M; Holtkamp U; Sander J
    J Clin Endocrinol Metab; 2007 Jul; 92(7):2581-9. PubMed ID: 17456574
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Steroid profile in dried blood spots by liquid chromatography tandem mass spectrometry: Application to newborn screening for congenital adrenal hyperplasia in China.
    Zhan X; Han L; Qiu W; Gu X; Guo J; Chang S; Wang Y; Zhang H
    Steroids; 2022 Sep; 185():109056. PubMed ID: 35660382
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of steroid profiling by UPLC-MS/MS as a second tier test in newborn screening for congenital adrenal hyperplasia: the Utah experience.
    Schwarz E; Liu A; Randall H; Haslip C; Keune F; Murray M; Longo N; Pasquali M
    Pediatr Res; 2009 Aug; 66(2):230-5. PubMed ID: 19390483
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improved specificity of newborn screening for congenital adrenal hyperplasia by second-tier steroid profiling using tandem mass spectrometry.
    Lacey JM; Minutti CZ; Magera MJ; Tauscher AL; Casetta B; McCann M; Lymp J; Hahn SH; Rinaldo P; Matern D
    Clin Chem; 2004 Mar; 50(3):621-5. PubMed ID: 14656905
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Determination of a steroid profile in heel prick blood using LC-MS/MS.
    Boelen A; Ruiter AF; Claahsen-van der Grinten HL; Endert E; Ackermans MT
    Bioanalysis; 2016; 8(5):375-84. PubMed ID: 26891684
    [TBL] [Abstract][Full Text] [Related]  

  • 8. False positive rate in newborn screening for congenital adrenal hyperplasia (CAH)-ether extraction reveals two distinct reasons for elevated 17alpha-hydroxyprogesterone (17-OHP) values.
    Fingerhut R
    Steroids; 2009 Aug; 74(8):662-5. PubMed ID: 19463687
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neonatal screening: identification of children with 11β-hydroxylase deficiency by second-tier testing.
    Janzen N; Riepe FG; Peter M; Sander S; Steuerwald U; Korsch E; Krull F; Müller HL; Heger S; Brack C; Sander J
    Horm Res Paediatr; 2012; 77(3):195-9. PubMed ID: 22508345
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pilot proficiency testing study for second tier congenital adrenal hyperplasia newborn screening.
    De Jesús VR; Simms DA; Schiffer J; Kennedy M; Mei JV; Hannon WH
    Clin Chim Acta; 2010 Nov; 411(21-22):1684-7. PubMed ID: 20619255
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Birth Weight- or Gestational Age-adjusted Second-tier LCMSMS Cutoffs Improve Newborn Screening for CAH in New Zealand.
    de Hora MR; Heather NL; Webster D; Albert BB; Hofman PL
    J Clin Endocrinol Metab; 2021 Aug; 106(9):e3390-e3399. PubMed ID: 34058748
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Implementing steroid profiling by liquid chromatography-tandem mass spectrometry improves newborn screening for congenital adrenal hyperplasia in New Zealand.
    de Hora MR; Heather NL; Patel T; Bresnahan LG; Webster D; Hofman PL
    Clin Endocrinol (Oxf); 2021 Jun; 94(6):904-912. PubMed ID: 33471388
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Simultaneous quantification of 17α-OH progesterone, 11-deoxycortisol, Δ4-androstenedione, cortisol and cortisone in newborn blood spots using liquid chromatography-tandem mass spectrometry.
    Magnisali P; Chalioti MB; Livadara T; Mataragas M; Paliatsiou S; Malamitsi-Puchner A; Moutsatsou P
    J Chromatogr B Analyt Technol Biomed Life Sci; 2011 Jun; 879(19):1565-72. PubMed ID: 21514253
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neonatal screening for congenital adrenal hyperplasia in Southern Brazil: a population based study with 108,409 infants.
    Kopacek C; de Castro SM; Prado MJ; da Silva CM; Beltrão LA; Spritzer PM
    BMC Pediatr; 2017 Jan; 17(1):22. PubMed ID: 28095810
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neonatal Screening for Congenital Adrenal Hyperplasia in Turkey: A Pilot Study with 38,935 Infants.
    Güran T; Tezel B; Gürbüz F; Selver Eklioğlu B; Hatipoğlu N; Kara C; Şimşek E; Çizmecioğlu FM; Ozon A; Baş F; Aydın M; Darendeliler F
    J Clin Res Pediatr Endocrinol; 2019 Feb; 11(1):13-23. PubMed ID: 30111524
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Concurrent Confirmation and Differential Diagnosis of Congenital Adrenal Hyperplasia from Dried Blood Spots: Application of a Second-Tier LC-MS/MS Assay in a Cross-Border Cooperation for Newborn Screening.
    Monostori P; Szabó P; Marginean O; Bereczki C; Karg E
    Horm Res Paediatr; 2015; 84(5):311-8. PubMed ID: 26397944
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Screening for congenital adrenal hyperplasia: adjustment of 17-hydroxyprogesterone cut-off values to both age and birth weight markedly improves the predictive value.
    Olgemöller B; Roscher AA; Liebl B; Fingerhut R
    J Clin Endocrinol Metab; 2003 Dec; 88(12):5790-4. PubMed ID: 14671170
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Twenty Years of Neonatal Screening for Congenital Adrenal Hyperplasia in North-Eastern Italy: Role of Liquid Chromatography-Tandem Mass Spectrometry as a Second-Tier Test.
    Cavarzere P; Camilot M; Palma L; Lauriola S; Gaudino R; Vincenzi M; Antoniazzi F; Teofoli F; Piacentini G
    Horm Res Paediatr; 2022; 95(3):255-263. PubMed ID: 35350013
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ketosteroid profiling using Girard T derivatives and electrospray ionization tandem mass spectrometry: direct plasma analysis of androstenedione, 17-hydroxyprogesterone and cortisol.
    Johnson DW
    Rapid Commun Mass Spectrom; 2005; 19(2):193-200. PubMed ID: 15593251
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hormonal disturbances due to severe and mild forms of congenital adrenal hyperplasia are already detectable in neonatal life.
    Faurschou S; Mouritsen A; Johannsen TH; Hougaard DM; Cohen A; Duno M; Juul A; Main KM
    Acta Paediatr; 2015 Feb; 104(2):e57-62. PubMed ID: 25346389
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.